N/A
N=37
Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
Lymphoma
Bottom Line
View on ClinicalTrials.gov: NCT03212261 ↗Enrolled (actual)
37
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions — 20 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 3RP-Lymphoma (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Massachusetts General Hospital
- Primary completion
- Jun 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions |
20 | — |
| PRIMARY Number of Participants Who Found the 3RP Program Acceptable |
21; 0; 21; 0; 21; 0 | — |
| SECONDARY Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples |
20; 14 | — |
Summary
The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).
Eligibility Criteria
Inclusion Criteria
- Aged 18-64
- Within 2 years post-treatment completion for lymphoma
- English speaking
- Able and willing to provide informed consent
- Cancer treatment or follow-up for lymphoma at the MGH Cancer Center
Exclusion Criteria
- Unwilling or unable to participate in the study
- Unable to speak or read English
- Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI)
- Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software
- Participation in qualitative interview during Phase 1 (DF/HCC 16-396)
Data sourced from ClinicalTrials.gov (NCT03212261). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.